Annotation Detail

Information
Associated Genes
NPM1
Associated Variants
NPM1 EXON 12 MUTATION
NPM1 EXON 12 MUTATION
Associated Disease
acute myeloid leukemia
Source Database
CIViC Evidence
Description
Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/176
Gene URL
https://civic.genome.wustl.edu/links/genes/35
Variant URL
https://civic.genome.wustl.edu/links/variants/86
Rating
5
Evidence Type
Prognostic
Disease
Acute Myeloid Leukemia
Evidence Direction
Supports
Evidence Level
B
Clinical Significance
Better Outcome
Pubmed
16076867
Drugs